Zuken Inc.
What does Zuken do?
Zuken sells engineering software used before physical products are built. CR-8000 helps engineers design printed circuit boards, E3.series helps design wire harnesses, and DS/PDM tools manage engineering data and product design records. License sales create the installed base, while Client Services contracts renew around that base and reached 42.9% of FY03/26 revenue. The core franchise now has to fund two new growth legs—GENESYS in model-based systems engineering and 3DIC packaging—while ¥36.1bn of net cash depresses returns. MBSE revenue, Americas losses, and capital-return follow-through will show whether those investments create value.
What has driven the stock over the past two years?
Operating leverage and capital returns supported the re-rating.
01 · THE RALLY Zuken's software sits early in the engineering workflow, before hardware is manufactured. CR-8000 is used for electronic design automation (EDA) of printed circuit boards, E3.series is used for wire-harness CAD, and DS/PDM tools manage engineering data across design teams. Once libraries and workflows are embedded, switching costs are high. That makes the revenue model cumulative: license sales build the installed base, Client Services contracts renew around it, and data-management usage deepens with each product generation.
02 · THE REVERSAL On August 6, 2025 the 1Q FY03/26 tanshin disclosed sales ¥9,119M (+1.1% YoY) and OP ¥827M (−3.4%) — an optical reversal that read as the front edge of a back-end-loaded year. The reasoning was visible in the same disclosure: the MTP had explicitly placed the heavier sales lift in years two and three, and the 1Q personnel-cost increase reflected the MBSE-related development spending management had built into the plan as a structural investment phase.
03 · WHERE WE STAND NOW The FY03/26 tanshin filed on May 14, 2026 closed the question on the 2H. The ¥3bn yen-cap buyback authorized in May 2025 completed in late January 2026 — the second consecutive year of near-full-envelope execution after FY03/25's ¥2.5bn programme — bringing the trailing-twelve-month total payout to 134% of net income and the treasury share count to 5.3% of the issued base.
What investors disagree about
Cash use, GENESYS, and regional profitability now shape the multiple.
- Two consecutive buybacks were almost fully executed, and Zuken added a DOE floor while lifting the dividend. Those actions show that capital returns are becoming more systematic, although cash still grew.
- Cash rose again in FY03/26 despite a ¥3bn buyback. Ten years of flexible M&A language produced only one small deal, so the surplus still lacks a credible use.
- The Americas loss halved from ¥785M to ¥392M, while chip-packaging partnerships and the MBSE plan show outside demand. The missing evidence is how many GENESYS pilots become paid licenses.
- Commercial MBSE buyers also use Cadence Helium, Siemens Polarion, and Mentor's E3D toolchain, where Zuken lacks an installed base. Zuken's strongest channel—Japanese business-machine and general-electronics OEMs—is also the weakest commercial MBSE buyer.
- The 15.1% CAGR is asserted rather than evidenced; no customer count or license-versus-pilot mix is disclosed.
- Asia earns a 29.2% margin on a small ¥2.14bn revenue base. That shows the software model can travel; the next challenge is scaling it through India and other markets.
- Thirty years of overseas operations have produced one structural product win in Europe and one breakeven-or-better region in Asia at a small revenue base; the MTP plans roughly +¥5.5bn of incremental Japanese revenue against +¥2.8bn overseas through FY03/28.
What could change over the next twelve months?
Three disclosures could make Zuken's growth and capital policy clearer.
- Zuken's cash still grows faster than distributions. A higher DOE floor, a total-return floor tied to FCF, or a ceiling on cash as a share of market value would force retained capital to compete with the operating business's return instead of sitting in deposits.
- Zuken has described the Americas as an investment region for four years without naming a breakeven date. Publishing that date, along with quarterly MBSE customer counts split between paid licenses and pilots, would show whether GENESYS is becoming a commercial business.
- PDM revenue no longer tracks the consulting-led businesses cleanly. Reporting MBSE, PDM, and 3DIC revenue separately each quarter would show how much of the FY03/28 OP target is being delivered by each growth program.
What has to be true for the stock to work from here?
The range depends on MBSE growth, overseas profit, and capital returns.
The bear band of ¥3,600–¥4,200 implies ~7–9x FY03/27 forward EV/OP — in line with the only listed JP software peer, Business Engineering (4828) at ~7.2x, and at parity with the JP private-buyer 7–10x cohort that Renesas paid for Altium in February 2024.
The bull band of ¥5,400–¥6,400 implies ~11–14x FY03/27 forward EV/OP — a re-rate above the ~7.2x its lone listed JP peer (4828) trades on, yet still well below the global EDA peer band of 17–22x at Cadence and Synopsys. The implied multiple at the upper bull band sits two turns above today's 9.8x.
This is not investment advice.
Japan Investor Interface Co., Ltd. ("JII") is an investor-relations (IR) consultancy. JII is not a registered investment advisor, financial advisor, broker-dealer, or securities firm in any jurisdiction. JII is not registered as a Financial Instruments Business Operator under Japan's Financial Instruments and Exchange Act. JII does not have an Investment Advisory and Agency Business registration and does not provide investment advice or solicit the purchase, sale, or holding of any security.
JII Compounders is an editorial publication. Each profile is an analytical study of how publicly disclosed information about a Japanese listed company has been received by the market. It is intended for educational and research purposes for IR professionals, finance students, journalists, and other readers interested in corporate disclosure practice. Nothing in this publication constitutes a recommendation, opinion, suggestion, or solicitation to buy, sell, or hold any security, derivative, or other financial instrument. Price targets, scenario ranges, multiples, and comparable-company references are illustrative of analytical method only and must not be interpreted as JII's investment opinion.
No reliance. The information presented may be incomplete, out of date, or incorrect. Forward-looking statements are inherently uncertain. Past price performance does not indicate future results. Estimates and scenario figures are not predictions and may not be achieved. JII makes no representation or warranty, express or implied, regarding the accuracy, completeness, timeliness, or reliability of any information in this publication.
No fiduciary or advisory relationship. Reading this publication does not create any advisory, fiduciary, or professional relationship between you and JII. Before making any investment, tax, accounting, legal, or other decision, you should consult qualified, licensed advisors in your jurisdiction and conduct your own independent due diligence based on primary disclosures issued by the company concerned.
Trademarks & data. Company names, logos, tickers, and product names referenced are the property of their respective owners. Share-price data is licensed from third-party providers. TradingView is a trademark of TradingView, Inc. All rights reserved.
Conflicts of interest. JII, its officers, and related parties do not hold or trade securities of companies covered in JII research. If JII has a paid engagement with a company covered in a publication, that relationship is disclosed in the relevant publication. JII's publications are for informational purposes only and do not constitute investment advice or a recommendation to buy or sell any security.
本資料は、日本の金融商品取引法に基づく投資助言・代理業ではなく、特定の有価証券の売買その他の取引の勧誘・推奨を目的とするものではありません。本資料は教育・研究を目的とした分析記事であり、JII（株式会社ジャパン・インベスター・インターフェース）は、本資料の内容に基づく投資判断について一切の責任を負いません。投資の判断はご自身の責任と独立した調査に基づいて行ってください。